alanine has been researched along with Hepatitis B, Chronic in 82 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It remains unknown whether tenofovir alafenamide (TAF) could replace tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV)." | 9.51 | Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. ( Byun, KS; Choi, J; Gwak, GY; Kim, JH; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC, 2022) |
| "Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs." | 9.51 | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. ( Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M, 2022) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 9.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection." | 9.34 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020) |
| " We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study." | 9.30 | Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. ( Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K, 2019) |
| "The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB)." | 9.22 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. ( Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y, 2022) |
| "Non-cirrhotic, treatment-naïve subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 weeks." | 9.20 | Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. ( Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015) |
| "Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection." | 8.95 | Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. ( Furusyo, N; Nguyen, MH; Ogawa, E, 2017) |
| "In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB)." | 8.95 | Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. ( Abdul Basit, S; Dawood, A; Gish, R; Ryan, J, 2017) |
| "Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)." | 8.95 | Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017) |
| "As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases." | 8.31 | Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. ( Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E, 2023) |
| "Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects." | 8.12 | Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022) |
| "Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments." | 8.12 | Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. ( Jeong, S; Kim, HI; Shin, HP, 2022) |
| "There are inadequate data and no histological evidence regarding the effects of antiviral treatment for hepatitis B e-antigen (HBeAg)-negative chronic hepatitis B (CHB) patients with normal or mildly elevated alanine aminotransferase (ALT)." | 8.12 | Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study. ( Chen, H; Hu, M; Li, H; Peng, J; Wang, P; Wei, S; Xie, Q, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 8.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection." | 8.12 | Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022) |
| "Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment." | 8.12 | One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. ( Chen, YC; Chien, RN; Hsu, CW; Tai, DI, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 8.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Persistent serum alanine aminotransferase (ALT) elevation in nucleotide/nucleoside analogue (NA)-treated patients with chronic hepatitis B (CHB) has been associated with unfavorable long-term outcomes." | 8.12 | Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. ( Daugherty, T; Goel, A; Kim, WR; Kwo, PY; Kwong, A; Mannalithara, A; Sripongpun, P, 2022) |
| "Tenofovir alafenamide (TAF) has been available in China for a short time, little is known about its safety and efficacy in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF)." | 8.02 | The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study. ( Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X, 2021) |
| "It is unclear whether tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) is more effective for preventing hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB)." | 8.02 | Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)." | 8.02 | Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. ( Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF, 2021) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 8.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Whether entecavir (ETV) or tenofovir alafenamide (TAF) is better at preventing hepatocellular carcinoma (HCC) development among patients with chronic hepatitis B (CHB) remains unclear." | 8.02 | Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB)." | 7.96 | Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. ( Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K, 2020) |
| "Enzymatic analysis of aspartate/alanine aminotransferase (AST/ALT) does not exactly represent the progression of liver fibrosis or inflammation." | 7.96 | Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation. ( Baik, GH; Bang, CS; Choi, EY; Ham, YL; Kim, DJ; Kim, HJ; Kim, SY; Shin, SP; Suk, KT; Yang, YJ, 2020) |
| "In noninvasive measurement of liver fibrosis (FibroScan®), the level of liver stiffness measurement (LSM) had decreased significantly at 48 weeks (5." | 7.11 | Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial. ( Cai, GS; Chen, HJ; Chen, JZ; Chen, L; Chi, XL; Gao, YQ; Guo, H; Jiang, JM; Lei, CL; Li, Q; Liu, HB; Lu, W; Mao, DW; Ou-Yang, WW; Shi, MJ; Tian, GJ; Wang, J; Wen, ZH; Wu, SD; Xiao, HM; Xie, YB; Xue, JD; Yang, HZ; Zhang, CZ; Zhao, PT, 2022) |
| "Long-term administration of TDF has resulted in stronger adverse effects than TAF and ETV in regard to both renal function and bone tissue in CHB patients." | 7.01 | Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023) |
| " The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported." | 7.01 | Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. ( Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021) |
| "Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development." | 5.62 | Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. ( Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH, 2021) |
| "Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs." | 5.51 | Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. ( Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M, 2022) |
| "It remains unknown whether tenofovir alafenamide (TAF) could replace tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV)." | 5.51 | Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. ( Byun, KS; Choi, J; Gwak, GY; Kim, JH; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC, 2022) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 5.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection." | 5.34 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020) |
| " We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study." | 5.30 | Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. ( Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K, 2019) |
| "The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB)." | 5.22 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. ( Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y, 2022) |
| "Non-cirrhotic, treatment-naïve subjects with chronic hepatitis B were randomized (1:1:1:1:1) to receive tenofovir alafenamide 8, 25, 40, or 120 mg, or tenofovir disoproxil fumarate 300 mg for 28 days and assessed for safety, antiviral response, and pharmacokinetics, followed-up by off-treatment for 4 weeks." | 5.20 | Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. ( Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S, 2015) |
| "Tenofovir disoproxil fumarate (TDF), an ester prodrug of tenofovir (TFV), is one of the recommended drugs for chronic hepatitis B (CHB) patients." | 4.98 | Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? ( Grossi, G; Lampertico, P; Loglio, A; Viganò, M, 2018) |
| "Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)." | 4.95 | Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017) |
| "Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection." | 4.95 | Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. ( Furusyo, N; Nguyen, MH; Ogawa, E, 2017) |
| "In April 2017 tenofovir alafenamide (TAF) was added to the list of first-line therapies recommended for chronic hepatitis B (CHB)." | 4.95 | Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. ( Abdul Basit, S; Dawood, A; Gish, R; Ryan, J, 2017) |
| "As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases." | 4.31 | Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. ( Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E, 2023) |
| "This retrospective study included 289 chronic hepatitis B (CHB) patients without cirrhosis who received entecavir (n = 93), TDF (n = 103), or TAF (n = 86) retreatment for at least 12 months after entecavir or TDF cessation." | 4.31 | Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. ( Chang, KC; Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Lu, SN; Wang, JH, 2023) |
| "Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment." | 4.12 | One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. ( Chen, YC; Chien, RN; Hsu, CW; Tai, DI, 2022) |
| "Tenofovir is a nucleotidic analog inhibitor used in monotherapy as first line treatment of chronic Hepatitis B virus (HBV) infection." | 4.12 | Treatment of chronic hepatitis B: virological and pharmacological aspects ( Foucault, T; Gaudy-Graffin, C; Handala, L; Marlet, J; Paintaud, G, 2022) |
| "There are inadequate data and no histological evidence regarding the effects of antiviral treatment for hepatitis B e-antigen (HBeAg)-negative chronic hepatitis B (CHB) patients with normal or mildly elevated alanine aminotransferase (ALT)." | 4.12 | Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study. ( Chen, H; Hu, M; Li, H; Peng, J; Wang, P; Wei, S; Xie, Q, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 4.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Persistent serum alanine aminotransferase (ALT) elevation in nucleotide/nucleoside analogue (NA)-treated patients with chronic hepatitis B (CHB) has been associated with unfavorable long-term outcomes." | 4.12 | Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. ( Daugherty, T; Goel, A; Kim, WR; Kwo, PY; Kwong, A; Mannalithara, A; Sripongpun, P, 2022) |
| "Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects." | 4.12 | Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022) |
| "Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments." | 4.12 | Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. ( Jeong, S; Kim, HI; Shin, HP, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 4.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection." | 4.12 | Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. ( Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N, 2022) |
| "Whether entecavir (ETV) or tenofovir alafenamide (TAF) is better at preventing hepatocellular carcinoma (HCC) development among patients with chronic hepatitis B (CHB) remains unclear." | 4.02 | Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "It is unclear whether tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) is more effective for preventing hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB)." | 4.02 | Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)." | 4.02 | Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. ( Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF, 2021) |
| "Tenofovir alafenamide (TAF) has been available in China for a short time, little is known about its safety and efficacy in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF)." | 4.02 | The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study. ( Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X, 2021) |
| "Real-world data for treatment effectiveness and renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) are limited." | 4.02 | Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. ( Arai, T; Asai, A; Atsukawa, M; Cheung, R; Chien, N; Chuma, M; Dang, H; Fukunishi, S; Henry, L; Hoang, J; Huang, DQ; Ishikawa, T; Landis, C; Le, RH; Leong, J; Lim, SG; Liu, J; Maeda, M; Nguyen, MH; Quek, SXZ; Senoo, T; Takaguchi, K; Thin, KN; Toyoda, H; Tran, S; Trinh, HN; Uojima, H; Watanabe, T; Yasuda, S; Yokohama, K, 2021) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 4.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB)." | 3.96 | Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. ( Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K, 2020) |
| "Enzymatic analysis of aspartate/alanine aminotransferase (AST/ALT) does not exactly represent the progression of liver fibrosis or inflammation." | 3.96 | Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation. ( Baik, GH; Bang, CS; Choi, EY; Ham, YL; Kim, DJ; Kim, HJ; Kim, SY; Shin, SP; Suk, KT; Yang, YJ, 2020) |
| "Tenofovir alafenamide (TAF) is the latest agent approved for chronic hepatitis B virus (HBV) treatment." | 3.96 | Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. ( Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P, 2020) |
| " The patient had been treated with lamivudine (LAM) in 2005, LAM+adefovir (ADV) in 2009, and ADV+entecavir in 2015 for chronic hepatitis B (CH-B)." | 3.91 | [Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels]. ( Hiraoka, A; Izumoto, H; Kitahata, S; Kondoh, K; Michitaka, K; Ninomiya, T; Tsubouchi, E; Ueki, H; Yamago, H, 2019) |
| "In noninvasive measurement of liver fibrosis (FibroScan®), the level of liver stiffness measurement (LSM) had decreased significantly at 48 weeks (5." | 3.11 | Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial. ( Cai, GS; Chen, HJ; Chen, JZ; Chen, L; Chi, XL; Gao, YQ; Guo, H; Jiang, JM; Lei, CL; Li, Q; Liu, HB; Lu, W; Mao, DW; Ou-Yang, WW; Shi, MJ; Tian, GJ; Wang, J; Wen, ZH; Wu, SD; Xiao, HM; Xie, YB; Xue, JD; Yang, HZ; Zhang, CZ; Zhao, PT, 2022) |
| "Long-term administration of TDF has resulted in stronger adverse effects than TAF and ETV in regard to both renal function and bone tissue in CHB patients." | 3.01 | Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023) |
| " The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported." | 3.01 | Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. ( Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021) |
| "Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression." | 2.58 | Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. ( Buti, M; Esteban, R; Riveiro-Barciela, M, 2018) |
| "Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis." | 1.72 | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. ( Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022) |
| " TAF was well tolerated and only 4 patients discontinued therapy due to adverse event during a median duration of TAF dosing of 74 weeks." | 1.72 | Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. ( Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC, 2022) |
| "Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development." | 1.62 | Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. ( Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH, 2021) |
| "To evaluate the impact of chronic hepatitis B virus infection (CHB) treatment on risk of cirrhosis, liver-related outcomes, and death among a diverse CHB cohort with a large proportion of African Americans." | 1.62 | Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. ( Jain, MK; Kshirsagar, O; Niu, B; Thamer, M; Therapondos, G; Wong, RJ, 2021) |
| "6%) patients because of adverse effects." | 1.62 | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. ( Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ, 2021) |
| " No severe adverse effects were reported in either mothers or infants." | 1.56 | Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. ( Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020) |
| "The prediction of hepatocellular carcinoma (HCC) development during nucleotide/nucleoside analog (NA) therapy is clinically important in patients with chronic hepatitis B." | 1.56 | Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y, 2020) |
| "Acquired Fanconi syndrome has been associated with the long-term ingestion of several nucleoside analogs used to treat chronic hepatitis B virus infection." | 1.51 | A case of entecavir-induced Fanconi syndrome. ( Fujii, T; Kawasoe, K; Nitta, K; Ohta, A, 2019) |
| "Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF)." | 1.46 | Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. ( Karris, MY, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.22) | 29.6817 |
| 2010's | 17 (20.73) | 24.3611 |
| 2020's | 64 (78.05) | 2.80 |
| Authors | Studies |
|---|---|
| Yeh, ML | 1 |
| Liang, PC | 1 |
| Trinh, S | 1 |
| Huang, CI | 1 |
| Huang, CF | 1 |
| Hsieh, MY | 1 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Chuang, WL | 4 |
| Nguyen, MH | 6 |
| Yu, ML | 1 |
| Jeong, S | 1 |
| Shin, HP | 1 |
| Kim, HI | 1 |
| Chon, HY | 1 |
| Ahn, SH | 5 |
| Kim, YJ | 2 |
| Yoon, JH | 1 |
| Lee, JH | 1 |
| Sinn, DH | 1 |
| Kim, SU | 4 |
| Jeong, J | 1 |
| Shin, JW | 1 |
| Jung, SW | 1 |
| Park, EJ | 1 |
| Park, NH | 1 |
| Kumada, T | 2 |
| Toyoda, H | 3 |
| Yasuda, S | 3 |
| Ito, T | 1 |
| Tanaka, J | 2 |
| Suzuki, K | 2 |
| Suda, G | 2 |
| Yamamoto, Y | 2 |
| Abiko, S | 1 |
| Kinoshita, K | 1 |
| Miyamoto, S | 1 |
| Sugiura, R | 1 |
| Kimura, M | 2 |
| Maehara, O | 2 |
| Yamada, R | 2 |
| Kitagataya, T | 2 |
| Shigesawa, T | 1 |
| Ohara, M | 2 |
| Kawagishi, N | 2 |
| Nakai, M | 2 |
| Sho, T | 2 |
| Natsuizaka, M | 2 |
| Morikawa, K | 2 |
| Ogawa, K | 2 |
| Sakamoto, N | 2 |
| Ogawa, E | 5 |
| Nakamuta, M | 3 |
| Koyanagi, T | 3 |
| Ooho, A | 3 |
| Furusyo, N | 4 |
| Kajiwara, E | 3 |
| Dohmen, K | 3 |
| Kawano, A | 3 |
| Satoh, T | 3 |
| Takahashi, K | 3 |
| Azuma, K | 3 |
| Yamashita, N | 4 |
| Sugimoto, R | 2 |
| Amagase, H | 2 |
| Kuniyoshi, M | 2 |
| Ichiki, Y | 2 |
| Morita, C | 2 |
| Kato, M | 3 |
| Shimoda, S | 3 |
| Nomura, H | 3 |
| Hayashi, J | 3 |
| Liu, JK | 1 |
| Vutien, P | 1 |
| Huang, DQ | 2 |
| Ishigami, M | 1 |
| Landis, CS | 1 |
| Lim, YS | 6 |
| Seto, WK | 4 |
| Kurosaki, M | 2 |
| Fung, S | 4 |
| Kao, JH | 1 |
| Hou, J | 1 |
| Gordon, SC | 1 |
| Flaherty, JF | 6 |
| Yee, LJ | 1 |
| Zhao, Y | 2 |
| Agarwal, K | 4 |
| Lampertico, P | 3 |
| Uchida, Y | 2 |
| Nakao, M | 2 |
| Yamada, S | 1 |
| Tsuji, S | 2 |
| Uemura, H | 2 |
| Kouyama, JI | 2 |
| Naiki, K | 2 |
| Sugawara, K | 2 |
| Nakayama, N | 2 |
| Imai, Y | 2 |
| Tomiya, T | 2 |
| Mochida, S | 2 |
| Lin, HY | 1 |
| Tseng, TC | 1 |
| Lim, J | 1 |
| Choi, WM | 1 |
| Shim, JH | 1 |
| Lee, D | 1 |
| Kim, KM | 1 |
| Lee, HC | 2 |
| Choi, J | 2 |
| Xiao, HM | 1 |
| Shi, MJ | 1 |
| Jiang, JM | 1 |
| Cai, GS | 1 |
| Xie, YB | 1 |
| Tian, GJ | 1 |
| Xue, JD | 1 |
| Mao, DW | 1 |
| Li, Q | 2 |
| Yang, HZ | 1 |
| Guo, H | 1 |
| Lei, CL | 1 |
| Lu, W | 1 |
| Chen, L | 1 |
| Liu, HB | 1 |
| Wang, J | 1 |
| Gao, YQ | 1 |
| Chen, JZ | 1 |
| Wu, SD | 1 |
| Chen, HJ | 1 |
| Zhao, PT | 1 |
| Zhang, CZ | 1 |
| Ou-Yang, WW | 1 |
| Wen, ZH | 1 |
| Chi, XL | 1 |
| Pan, CQ | 4 |
| Afdhal, NH | 1 |
| Ankoma-Sey, V | 1 |
| Bae, H | 2 |
| Curry, MP | 1 |
| Dieterich, D | 1 |
| Frazier, L | 1 |
| Frick, A | 1 |
| Hann, HW | 1 |
| Kim, WR | 3 |
| Kwo, P | 1 |
| Milligan, S | 1 |
| Tong, MJ | 1 |
| Reddy, KR | 1 |
| Kayes, T | 1 |
| Crane, H | 1 |
| Symonds, A | 1 |
| Dumond, J | 1 |
| Cottrell, M | 1 |
| Di Girolamo, J | 1 |
| Manandhar, S | 1 |
| Lim, TH | 1 |
| Gane, E | 4 |
| Kashuba, A | 2 |
| Levy, MT | 2 |
| Papatheodoridis, GV | 2 |
| Mimidis, K | 1 |
| Manolakopoulos, S | 1 |
| Gatselis, N | 1 |
| Goulis, J | 1 |
| Kapatais, A | 1 |
| Manesis, E | 1 |
| Vasiliadis, T | 1 |
| Triantos, C | 1 |
| Samonakis, D | 1 |
| Sevastianos, V | 1 |
| Karatapanis, S | 1 |
| Elefsiniotis, I | 1 |
| Deutsch, M | 1 |
| Mylopoulou, T | 1 |
| Papatheodoridi, M | 1 |
| Kranidioti, H | 1 |
| Agorastou, P | 1 |
| Karaoulani, T | 1 |
| Kyriazidou, A | 1 |
| Zisimopoulos, K | 1 |
| Dalekos, GN | 1 |
| Chen, YC | 1 |
| Hsu, CW | 1 |
| Chien, RN | 1 |
| Tai, DI | 1 |
| Foucault, T | 1 |
| Handala, L | 1 |
| Paintaud, G | 1 |
| Gaudy-Graffin, C | 1 |
| Marlet, J | 1 |
| Kumar, M | 1 |
| Lee, MH | 1 |
| Hu, X | 1 |
| Li, R | 1 |
| Zang, M | 1 |
| Yuan, G | 1 |
| Chen, J | 1 |
| Tseng, TN | 1 |
| Chen, CH | 2 |
| Jung, CY | 1 |
| Kim, HW | 1 |
| Lee, JI | 1 |
| Lee, HW | 4 |
| Kim, BS | 1 |
| Chiu, SM | 1 |
| Chang, KC | 1 |
| Hu, TH | 1 |
| Hung, CH | 1 |
| Wang, JH | 1 |
| Lu, SN | 1 |
| Wei, S | 1 |
| Hu, M | 1 |
| Chen, H | 1 |
| Xie, Q | 1 |
| Wang, P | 1 |
| Li, H | 1 |
| Peng, J | 1 |
| Wang, ML | 1 |
| Chen, EQ | 1 |
| Sato, K | 1 |
| Inoue, J | 1 |
| Akahane, T | 1 |
| Kobayashi, T | 2 |
| Sato, S | 1 |
| Kisara, N | 1 |
| Ninomiya, M | 1 |
| Iwata, T | 1 |
| Sano, A | 1 |
| Tsuruoka, M | 1 |
| Onuki, M | 1 |
| Masamune, A | 1 |
| Baba, M | 1 |
| Hosoda, S | 1 |
| Yoshida, S | 1 |
| Kubo, A | 1 |
| Fu, Q | 1 |
| Yang, Z | 1 |
| Tokuchi, Y | 1 |
| Ohnishi, S | 1 |
| Furuya, K | 1 |
| Izumi, T | 1 |
| Meguro, T | 1 |
| Terashita, K | 1 |
| Ito, J | 1 |
| Tsunematsu, I | 1 |
| Cheng, CH | 1 |
| Hung, HC | 1 |
| Lee, JC | 1 |
| Wang, YC | 1 |
| Wu, TH | 1 |
| Lee, CF | 1 |
| Wu, TJ | 1 |
| Chou, HS | 1 |
| Chan, KM | 1 |
| Lee, WC | 1 |
| Hwang, EG | 1 |
| Jung, EA | 1 |
| Yoo, JJ | 1 |
| Kim, SG | 1 |
| Kim, YS | 1 |
| Kim, E | 1 |
| Kim, SS | 1 |
| Yoon, E | 1 |
| Jang, ES | 1 |
| Chang, JI | 1 |
| Cho, YY | 3 |
| Seo, GH | 1 |
| Kim, HJ | 3 |
| Liu, Z | 2 |
| Zhao, Z | 1 |
| Ma, X | 2 |
| Liu, S | 1 |
| Xin, Y | 1 |
| Motoya, D | 1 |
| Kirino, S | 1 |
| Tamaki, N | 1 |
| Kaneko, S | 1 |
| Inada, K | 1 |
| Yamashita, K | 1 |
| Osawa, L | 1 |
| Hayakawa, Y | 1 |
| Sekiguchi, S | 1 |
| Watakabe, K | 1 |
| Okada, M | 1 |
| Wang, W | 1 |
| Shimizu, T | 1 |
| Higuchi, M | 1 |
| Takaura, K | 1 |
| Maeyashiki, C | 1 |
| Yasui, Y | 1 |
| Nakanishi, H | 1 |
| Tsuchiya, K | 1 |
| Itakura, J | 1 |
| Takahashi, Y | 1 |
| Izumi, N | 2 |
| Mak, LY | 1 |
| Buti, M | 4 |
| Tak, WY | 1 |
| Ramji, A | 2 |
| Chen, CY | 2 |
| Tam, E | 2 |
| Gaggar, A | 4 |
| Lau, A | 1 |
| Liu, Y | 3 |
| Wu, G | 1 |
| Suri, V | 1 |
| Tan, SK | 2 |
| Subramanian, GM | 4 |
| Trinh, H | 1 |
| Yoon, SK | 1 |
| Chan, HLY | 2 |
| Tada, T | 1 |
| Miyake, N | 1 |
| Charlton, MR | 1 |
| Alam, A | 1 |
| Shukla, A | 1 |
| Dashtseren, B | 1 |
| Lesmana, CRA | 1 |
| Duger, D | 1 |
| Payawal, DA | 1 |
| Duy Cuong, D | 1 |
| Jargalsaikhan, G | 1 |
| Cua, IHY | 1 |
| Sollano, JD | 1 |
| Singh, KR | 1 |
| Madan, K | 1 |
| Win, KM | 1 |
| Kyi, KP | 1 |
| Tun, KS | 1 |
| Salih, M | 1 |
| Rastogi, M | 1 |
| Saraf, N | 1 |
| Thuy, PTT | 1 |
| Hien, PTD | 1 |
| Gani, RA | 1 |
| Mohamed, R | 1 |
| Tanwandee, T | 1 |
| Piratvisuth, T | 1 |
| Sukeepaisarnjaroen, W | 1 |
| Naing, W | 1 |
| Hashmi, ZY | 1 |
| Ding, Y | 1 |
| Cao, L | 1 |
| Zhu, L | 1 |
| Huang, Y | 1 |
| Lin, C | 1 |
| Wang, Y | 3 |
| Sheng, Q | 1 |
| Wang, S | 1 |
| Fan, J | 1 |
| Chen, R | 1 |
| Gan, W | 1 |
| Chen, B | 1 |
| Yip, TC | 2 |
| Wong, GL | 2 |
| Huang, YS | 1 |
| Cheng, CY | 1 |
| Liou, BH | 1 |
| Lu, PL | 1 |
| Cheng, SH | 1 |
| Lee, YT | 1 |
| Liu, CE | 1 |
| Sun, HY | 1 |
| Yang, CJ | 1 |
| Tang, HJ | 1 |
| Lin, SP | 1 |
| Ho, MW | 1 |
| Huang, SH | 1 |
| Tsai, HC | 1 |
| Lee, CH | 1 |
| Hung, CC | 1 |
| Sripongpun, P | 2 |
| Mannalithara, A | 2 |
| Kwong, A | 1 |
| Daugherty, T | 1 |
| Goel, A | 1 |
| Kwo, PY | 2 |
| Zeng, QL | 1 |
| Yu, ZJ | 1 |
| Ji, F | 1 |
| Li, GM | 1 |
| Zhang, GF | 1 |
| Xu, JH | 1 |
| Chen, ZM | 1 |
| Cui, GL | 1 |
| Li, W | 1 |
| Zhang, DW | 1 |
| Li, J | 4 |
| Lv, J | 1 |
| Li, ZQ | 1 |
| Liang, HX | 1 |
| Sun, CY | 1 |
| Pan, YJ | 1 |
| Liu, YM | 1 |
| Wang, FS | 1 |
| Li, ZB | 1 |
| Li, L | 1 |
| Niu, XX | 1 |
| Chen, SH | 1 |
| Fu, YM | 1 |
| Wang, CY | 1 |
| Shao, Q | 1 |
| Chen, G | 1 |
| Ji, D | 1 |
| Zhang, Y | 1 |
| Xu, W | 1 |
| Zhu, X | 1 |
| Li, X | 2 |
| Shu, X | 1 |
| Lai, J | 1 |
| Xie, J | 1 |
| Xie, C | 1 |
| Peng, L | 1 |
| Wong, RJ | 1 |
| Jain, MK | 1 |
| Therapondos, G | 1 |
| Niu, B | 1 |
| Kshirsagar, O | 1 |
| Thamer, M | 1 |
| Leong, J | 1 |
| Landis, C | 1 |
| Atsukawa, M | 1 |
| Watanabe, T | 1 |
| Liu, J | 2 |
| Quek, SXZ | 1 |
| Ishikawa, T | 1 |
| Arai, T | 1 |
| Yokohama, K | 1 |
| Chuma, M | 1 |
| Takaguchi, K | 1 |
| Uojima, H | 1 |
| Senoo, T | 1 |
| Dang, H | 1 |
| Maeda, M | 1 |
| Hoang, J | 1 |
| Le, RH | 1 |
| Thin, KN | 1 |
| Tran, S | 1 |
| Chien, N | 1 |
| Henry, L | 1 |
| Asai, A | 1 |
| Fukunishi, S | 1 |
| Cheung, R | 1 |
| Lim, SG | 1 |
| Trinh, HN | 2 |
| Farag, MS | 1 |
| Doucette, K | 1 |
| Wong, A | 1 |
| Conway, B | 1 |
| Cooper, C | 1 |
| Tsoi, K | 1 |
| Wong, P | 1 |
| Sebastiani, G | 1 |
| Brahmania, M | 1 |
| Haylock-Jacobs, S | 1 |
| Coffin, CS | 2 |
| Hansen, BE | 1 |
| Janssen, HLA | 1 |
| Hui, VW | 1 |
| Wong, VW | 1 |
| Tse, YK | 1 |
| Chan, HL | 3 |
| Lui, GC | 1 |
| Byun, KS | 1 |
| Kim, JH | 1 |
| Lee, YS | 1 |
| Yoo, BC | 1 |
| Kwon, SY | 1 |
| Gwak, GY | 1 |
| Chang, TT | 1 |
| Bae, SH | 1 |
| Brunetto, M | 2 |
| Mo, S | 1 |
| Çelen, MK | 1 |
| Thompson, A | 1 |
| Gane, EJ | 2 |
| Bernstein, DE | 1 |
| Schiff, ER | 1 |
| Smith, CI | 1 |
| Mospan, AR | 1 |
| Zink, RC | 1 |
| Fried, MW | 1 |
| Lok, AS | 1 |
| Hu, C | 1 |
| Chen, Y | 1 |
| Zhang, R | 2 |
| Fu, S | 1 |
| Zhou, M | 1 |
| Gao, Z | 1 |
| Fu, M | 1 |
| Yan, T | 1 |
| Yang, Y | 1 |
| Chen, T | 1 |
| He, Y | 1 |
| Marcos-Fosch, C | 1 |
| Esteban, R | 2 |
| Li, B | 1 |
| Liu, X | 1 |
| Liu, D | 1 |
| Duan, M | 1 |
| Gu, Y | 1 |
| Liu, Q | 1 |
| Ma, Q | 1 |
| Wei, Y | 1 |
| Lee, H | 2 |
| Lee, JS | 2 |
| Park, JY | 2 |
| Kim, DY | 2 |
| Kim, BK | 2 |
| Park, SY | 2 |
| Karris, MY | 1 |
| Hui, AJ | 2 |
| Janssen, HL | 2 |
| Chowdhury, A | 1 |
| Tsang, TY | 1 |
| Mehta, R | 2 |
| Massetto, B | 2 |
| Kitrinos, KM | 1 |
| Lin, L | 1 |
| McHutchison, JG | 3 |
| Acharya, SK | 2 |
| Stepanova, T | 1 |
| Cathcart, AL | 1 |
| Kim, K | 1 |
| Marcellin, P | 1 |
| Abdul Basit, S | 1 |
| Dawood, A | 1 |
| Ryan, J | 1 |
| Gish, R | 1 |
| Scott, LJ | 1 |
| Heo, NY | 1 |
| Hsu, YC | 1 |
| Wei, MT | 1 |
| Tartaglia, A | 1 |
| Ferrara, SM | 1 |
| Sica, S | 1 |
| Santantonio, T | 1 |
| Viganò, M | 1 |
| Loglio, A | 1 |
| Grossi, G | 1 |
| Riveiro-Barciela, M | 1 |
| Fong, TL | 1 |
| Lee, BT | 1 |
| Tien, A | 1 |
| Chang, M | 1 |
| Lim, C | 1 |
| Ahn, A | 1 |
| Bae, HS | 1 |
| Kim, SY | 1 |
| Shin, SP | 1 |
| Yang, YJ | 1 |
| Bang, CS | 1 |
| Baik, GH | 1 |
| Kim, DJ | 1 |
| Ham, YL | 1 |
| Choi, EY | 1 |
| Suk, KT | 1 |
| Kondoh, K | 1 |
| Michitaka, K | 1 |
| Hiraoka, A | 1 |
| Izumoto, H | 1 |
| Ueki, H | 1 |
| Kitahata, S | 1 |
| Yamago, H | 1 |
| Tsubouchi, E | 1 |
| Ninomiya, T | 1 |
| Fujii, T | 1 |
| Kawasoe, K | 1 |
| Ohta, A | 1 |
| Nitta, K | 1 |
| Hagiwara, S | 1 |
| Nishida, N | 1 |
| Ida, H | 1 |
| Ueshima, K | 1 |
| Minami, Y | 1 |
| Takita, M | 1 |
| Komeda, Y | 1 |
| Kudo, M | 1 |
| Fung, SK | 1 |
| Nguyen, TT | 1 |
| Cheng, W | 1 |
| Sicard, E | 1 |
| Ryder, SD | 1 |
| Lawson, E | 1 |
| Zhao, S | 1 |
| Foster, GR | 1 |
| Garcia, M | 1 |
| Le Moal, G | 1 |
| Godet, C | 1 |
| Beraud, G | 1 |
| Chagneau-Derrode, C | 1 |
| Roblot, F | 1 |
| Deng, G | 1 |
| Zhou, G | 1 |
| Zhai, Y | 1 |
| Li, S | 1 |
| Li, Y | 1 |
| Yao, Z | 1 |
| Shen, Y | 1 |
| Qiang, B | 1 |
| He, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy[NCT05583006] | 60 participants (Anticipated) | Observational | 2023-11-06 | Recruiting | |||
| A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection[NCT05410496] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-06-22 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25 mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed[NCT02979613] | Phase 3 | 490 participants (Actual) | Interventional | 2016-12-29 | Completed | ||
| Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)[NCT04724785] | 10,000 participants (Anticipated) | Observational | 2020-12-01 | Recruiting | |||
| To Evaluate the Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B (CHB) Patients With Low-level Viraemia (LLV) After Entecavir Treatment[NCT05755776] | 204 participants (Anticipated) | Observational | 2023-03-01 | Recruiting | |||
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
| Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir[NCT03241641] | Phase 4 | 174 participants (Actual) | Interventional | 2017-10-26 | Completed | ||
| An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection[NCT03692897] | 5,000 participants (Anticipated) | Observational | 2018-10-11 | Recruiting | |||
| A Multicenter Controlled Open-label Trial of Evaluating Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate and Entecavir in Acute-on-chronic Liver Failure of Chronic Hepatitis B Patients[NCT03640728] | 200 participants (Anticipated) | Observational | 2019-01-25 | Recruiting | |||
| Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study[NCT04939441] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-20 | Active, not recruiting | ||
| Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Mother-to-child Transmission in the Third Trimester: a Multicenter, Prospective Study[NCT04237376] | 600 participants (Anticipated) | Observational | 2019-04-09 | Recruiting | |||
| Safety and Efficacy of Tenofovir Alafenamide for Chronic Hepatitis B Patients With Decompensated Liver Disease[NCT04683341] | Phase 4 | 100 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B[NCT01940471] | Phase 3 | 875 participants (Actual) | Interventional | 2013-09-11 | Completed | ||
| Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial[NCT03933384] | Phase 4 | 420 participants (Anticipated) | Interventional | 2019-08-19 | Recruiting | ||
| Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy[NCT04201808] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B[NCT01940341] | Phase 3 | 426 participants (Actual) | Interventional | 2013-09-12 | Completed | ||
| "Analysis of Proximal Renal Tubular Function of Real World Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF"[NCT02957994] | Phase 4 | 82 participants (Actual) | Interventional | 2016-12-22 | Active, not recruiting | ||
| The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477] | Phase 4 | 64 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 96 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | mL/min (Median) |
|---|---|
| TAF 25 mg | 1.626 |
| TDF 300 mg | 0.544 |
"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 48 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | mL/min (Median) |
|---|---|
| TAF 25 mg | 2.240 |
| TDF 300 mg | -1.722 |
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| TAF 25 mg | -0.02 |
| TDF 300 mg | -0.01 |
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | scores on a scale (Mean) |
|---|---|
| TAF 25 mg | -0.03 |
| TDF 300 mg | -0.03 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 1.157 |
| TDF 300 mg | 0.180 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 0.659 |
| TDF 300 mg | -0.507 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 1.743 |
| TDF 300 mg | -0.138 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| TAF 25 mg | 2.330 |
| TDF 300 mg | 1.726 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 17.9 |
| TDF 300 mg | 9.0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 2.6 |
| TDF 300 mg | 0.0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 5.1 |
| TDF 300 mg | 2.6 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 1.6 |
| TDF 300 mg | 2.4 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.0 |
| TDF 300 mg | 0.0 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.8 |
| TDF 300 mg | 0.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. Missing=Failure (M = F) approach was used for analysis. (NCT02979613)
Timeframe: Weeks 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 96.3 |
| TDF 300 mg | 96.3 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 94.7 |
| TDF 300 mg | 93.9 |
"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 96 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 96 analysis window (from Day 589 to Day 840, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 96 analysis window and~Discontinued study drug prior to or in the Week 96 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 96 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.4 |
| TDF 300 mg | 0.4 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 7.7 |
| TDF 300 mg | 6.4 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.0 |
| TDF 300 mg | 2.0 |
"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 48 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 48 analysis window (from Day 295 to Day 378, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 48 analysis window and~Discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 48 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 0.4 |
| TDF 300 mg | 0.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 48, was handled by M = F, and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| M = F Approach: < 20 IU/mL Target Not Detected | M = F Approach: < 20 IU/mL Target Detected | M = E Approach: < 20 IU/mL Target Not Detected | M = E Approach: < 20 IU/mL Target Detected | |
| TAF 25 mg | 63.4 | 32.9 | 65.5 | 34.0 |
| TDF 300 mg | 62.0 | 34.3 | 64.1 | 35.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 96, was handled by Missing=Failure (M = F), and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| M = F Approach: < 20 IU/mL Target Not Detected | M = F Approach: < 20 IU/mL Target Detected | M = E Approach: < 20 IU/mL Target Not Detected | M = E Approach: < 20 IU/mL Target Detected | |
| TAF 25 mg | 65.8 | 28.8 | 69.3 | 30.3 |
| TDF 300 mg | 66.1 | 27.8 | 70.1 | 29.4 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 89.3 | 79.0 |
| TDF 300 mg | 84.9 | 75.1 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 88.5 | 80.7 |
| TDF 300 mg | 91.4 | 86.5 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 50.0 | 50.0 |
| TDF 300 mg | 36.8 | 26.4 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Central Laboratory Criteria | AASLD Criteria | |
| TAF 25 mg | 56.3 | 55.8 |
| TDF 300 mg | 78.9 | 73.6 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| TAF 25 mg | 0.009 |
| TDF 300 mg | 0.026 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.100 |
| TDF 300 mg | -1.715 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.417 |
| TDF 300 mg | -2.294 |
(NCT01940471)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 10.3 |
| TDF 300 mg | 8.1 |
(NCT01940471)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 63.9 |
| TDF 300 mg | 66.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940471)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| TAF 25 mg | 23.9 | 3.5 | 0 |
| TDF 300 mg | 17.8 | 4.5 | 0.3 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| TAF 25 mg | 0.01 |
| TDF 300 mg | 0.02 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.288 |
| TDF 300 mg | -2.156 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.876 |
| TDF 300 mg | -2.514 |
The primary efficacy endpoint was determined by the achievement of HBV DNA < 29 IU/mL at Week 48. (NCT01940341)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| TAF 25 mg | 94.0 |
| TDF 300 mg | 92.9 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940341)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| TAF 25 mg | 18.1 | 1.1 | 0 |
| TDF 300 mg | 16.4 | 2.1 | 0 |
10 reviews available for alanine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H | 2023 |
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B, | 2023 |
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Topics: Alanine; Antiviral Agents; Asia; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Randomized Co | 2020 |
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Hepatitis B e Ant | 2017 |
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, | 2017 |
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glo | 2017 |
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Molecula | 2017 |
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chr | 2018 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reac | 2018 |
12 trials available for alanine and Hepatitis B, Chronic
60 other studies available for alanine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; | 2022 |
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver N | 2022 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Topics: Aged; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B, Chron | 2021 |
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Topics: Adenine; Alanine; Cholesterol; Hepatitis B, Chronic; Humans; Propensity Score; Tenofovir | 2022 |
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, C | 2021 |
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens | 2022 |
Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Kidney; Liver Transplantation; Ten | 2023 |
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Topics: Aged; Alanine; Antiviral Agents; Drug Substitution; Female; Follow-Up Studies; Fumarates; Genotype; | 2022 |
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; | 2022 |
First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Prospective Studies; Retrospec | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; | 2022 |
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insuffici | 2022 |
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studi | 2022 |
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis | 2022 |
Treatment of chronic hepatitis B: virological and pharmacological aspects
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human; | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Huma | 2022 |
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepati | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Long | 2022 |
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Recurrence; Retreatmen | 2023 |
Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.
Topics: Alanine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Sur | 2022 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis B virus; Hepatitis B, Chroni | 2023 |
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li | 2023 |
Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea.
Topics: Adenine; Adult; Alanine; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Osteoporotic Fract | 2023 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; H | 2020 |
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
Topics: Adenine; Alanine; Antiviral Agents; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Glomerular | 2020 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Teno | 2021 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Teno | 2021 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Teno | 2021 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Teno | 2021 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospec | 2020 |
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, V | 2020 |
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B | 2020 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; E | 2021 |
Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B.
Topics: Alanine; Alanine Transaminase; Antiviral Agents; Diabetes Mellitus; Hepatitis B, Chronic; Humans; Te | 2022 |
Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Topics: Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infant, Newbor | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospe | 2021 |
The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
Topics: Acute-On-Chronic Liver Failure; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, | 2021 |
Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
Topics: Adult; Aged; Alanine; Antiviral Agents; Asian; Black or African American; Carcinoma, Hepatocellular; | 2021 |
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Topics: Adult; Aged; Alanine; Alanine Transaminase; DNA, Viral; Drug Substitution; Female; Glomerular Filtra | 2021 |
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Topics: Alanine; Canada; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2021 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combinatio | 2021 |
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; M | 2022 |
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver N | 2021 |
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; | 2021 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infectio | 2017 |
Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
Topics: Alanine; Alanine Transaminase; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Huma | 2017 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, | 2017 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Femal | 2019 |
Immunological measurement of aspartate/alanine aminotransferase in predicting liver fibrosis and inflammation.
Topics: Alanine; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Biomarkers; Biopsy; Hepat | 2020 |
[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].
Topics: Adenine; Alanine; Alkaline Phosphatase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, V | 2019 |
A case of entecavir-induced Fanconi syndrome.
Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; | 2019 |
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir | 2020 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syn | 2016 |
Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection.
Topics: Adult; Alanine; Alleles; Asian People; Chromosome Mapping; Cysteine; Estrogen Receptor alpha; Female | 2004 |